AbbVie’s NDA has been accepted by the FDA for a once-daily, fixed-dose formulation of the components of VIEKIRA PAK (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets). VIEKIRA PAK is an all-oral, interferon-free treatment approved with or without ribavirin (RBV) in the U.S. for genotype 1 (GT1) chronic hepatitis C virus (HCV) infection. This drug would compete with other, more convenient dosing regimens for HCV, including Gilead’s once-daily, single-tablet regimen Harvoni. ...